New biomarker may unlock better treatment for Right-Sided colon cancer
NCT ID NCT07094893
First seen Jan 17, 2026 · Last updated May 09, 2026 · Updated 18 times
Summary
This study looks at whether a biomarker test (EREG/AREG) can help decide if adding a targeted drug (cetuximab) to standard chemotherapy works better for people with advanced right-sided colorectal cancer. About 280 adults with wild-type RAS tumors will be enrolled. The goal is to see if this approach leads to faster tumor shrinkage and longer survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.